open access

Vol 67, No 3 (2016)
Postgraduate education
Published online: 2016-02-01
Submitted: 2015-11-14
Accepted: 2015-11-15
Get Citation

Diagnosis, treatment, and prognosis in patients with liver metastases from follicular thyroid carcinoma (FTC)

Małgorzata Kałużna, Monika Gołąb, Rafał Czepczyński, Grzegorz Dworacki, Danuta Bręborowicz, Marcin Orłowski, Katarzyna Katulska, Aleksandra Klimowicz, Maria Gryczyńska, Marek Ruchała, Katarzyna Ziemnicka
DOI: 10.5603/EP.a2016.0040
·
Endokrynologia Polska 2016;67(3):332-347.

open access

Vol 67, No 3 (2016)
Postgraduate education
Published online: 2016-02-01
Submitted: 2015-11-14
Accepted: 2015-11-15

Abstract

Follicular thyroid carcinoma (FTC) is the second most common type of thyroid cancer (TC) and accounts for approximately 10% of all TC cases. Liver metastases are a rare presentation in 0.5–1% of follicular thyroid cancers, usually occurring in the setting of widely disseminated FTC disease, and their presence is associated with poor prognosis. Until now, there have been only 30 cases of FTC liver metastases described in the literature.

Herein, we review publications and describe diagnostic tools that may be used in the diagnosis and follow-up of FTC metastases to the liver, including biopsy and imaging techniques like US, CT, MRI, SPECT, PET, and radioiodine scintigraphy. We also present and discuss current methods of treatment, e.g. TSH suppressive therapy with levothyroxine, surgery, radiofrequency ablation (RFA), transarterial embolisation (TAE), liver transarterial chemoembolisation (TACE), chemotherapy with cisplatin and doxorubicin, treatment with Indium- 111-octreotide (or its analogues), and tyrosine kinase inhibitors (sorafenib, sunitinib).

At the end we describe the course, results of diagnostics, and treatment in a patient with large multiple FTC metastases to the liver. (Endokrynol Pol 2016; 67 (3): 332–347)

Abstract

Follicular thyroid carcinoma (FTC) is the second most common type of thyroid cancer (TC) and accounts for approximately 10% of all TC cases. Liver metastases are a rare presentation in 0.5–1% of follicular thyroid cancers, usually occurring in the setting of widely disseminated FTC disease, and their presence is associated with poor prognosis. Until now, there have been only 30 cases of FTC liver metastases described in the literature.

Herein, we review publications and describe diagnostic tools that may be used in the diagnosis and follow-up of FTC metastases to the liver, including biopsy and imaging techniques like US, CT, MRI, SPECT, PET, and radioiodine scintigraphy. We also present and discuss current methods of treatment, e.g. TSH suppressive therapy with levothyroxine, surgery, radiofrequency ablation (RFA), transarterial embolisation (TAE), liver transarterial chemoembolisation (TACE), chemotherapy with cisplatin and doxorubicin, treatment with Indium- 111-octreotide (or its analogues), and tyrosine kinase inhibitors (sorafenib, sunitinib).

At the end we describe the course, results of diagnostics, and treatment in a patient with large multiple FTC metastases to the liver. (Endokrynol Pol 2016; 67 (3): 332–347)

Get Citation

Keywords

differentiated thyroid carcinoma (DTC); follicular thyroid cancer (FTC); liver metastases; positron emission tomography (PET); whole body scintigraphy (WBS)

Supplementary Files (3)
Title page in english
Download
21KB
Authors consent 1
View
1MB
Authors consent 2
View
1MB
About this article
Title

Diagnosis, treatment, and prognosis in patients with liver metastases from follicular thyroid carcinoma (FTC)

Journal

Endokrynologia Polska

Issue

Vol 67, No 3 (2016)

Pages

332-347

Published online

2016-02-01

DOI

10.5603/EP.a2016.0040

Bibliographic record

Endokrynologia Polska 2016;67(3):332-347.

Keywords

differentiated thyroid carcinoma (DTC)
follicular thyroid cancer (FTC)
liver metastases
positron emission tomography (PET)
whole body scintigraphy (WBS)

Authors

Małgorzata Kałużna
Monika Gołąb
Rafał Czepczyński
Grzegorz Dworacki
Danuta Bręborowicz
Marcin Orłowski
Katarzyna Katulska
Aleksandra Klimowicz
Maria Gryczyńska
Marek Ruchała
Katarzyna Ziemnicka

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl